Invitrogen™ IFN beta Monoclonal Antibody (A1 (IFNb)), FITC, eBioscience™

Description

Description: The IFNb/A1 clone recognizes natural human IFN-beta and recombinants beta1a and beta1b. It is capable of neutralizing IFN-beta. Interferon beta is synthesized and secreted by fibroblasts and many other cell types in response to pathogens. IFN-beta binding to type I interferon receptors induces the upregulation of IRF-7 and activation of Rnase L. IRF-7 can exert a positive feedback on IFN-beta production. RNase L cleaves both viral and cellular single stranded mRNA, thereby limiting viral replication and dissemination. Applications Tested: ELISA, Neutralization tests, Western Blotting. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.

Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.